Skip to main content
Equibles
QURE logo

QURE · uniQure N.V. · Earnings Call Transcripts & Audio

Track QURE — free

Use QURE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research QURE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.16 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$2.41B
Shares
63.07M
Volume · Sep 30 7.44M Avg daily vol (3M) 1.9M

uniQure N.V. Earnings Call Transcripts

Quarterly earnings calls for uniQure N.V. (QURE), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼38% $1.53M '20 Q2 20-07-31 ▼99.9% $497,000 '22 Q2 22-08-08 ▼81.5% $1.57M −$43.64M '25 Q1 25-06-02 ▼52.7% $5.26M −$37.72M '25 Q2 25-07-29 ▲61.8% $3.70M −$80.53M '25 Q3 25-11-10 ▲6.6% $5.57M −$37.09M '25 Q4 26-03-02 LATEST ▲127.3% $3.56M −$53.53M '26 Q1 26-05-05
Earnings call
FY26 · Q2
2026-07-29
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
Confident tone AMT-130 Huntington's disease regulatory progress AMT-130 long-term clinical data FDA confirmatory trial design
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Balanced tone AMT-130 in Huntington's disease UK MHRA submission UK commercial readiness and access
Revenue
$3.56M
▲ 127.3% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Cautious tone FDA feedback on regulatory path for AMT-130 Phase III sham-controlled study requirement External comparator from natural history data
Revenue
$5.57M*
▲ 6.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Cautious tone FDA pre-BLA feedback and regulatory uncertainty AMT-130 Huntington's disease pivotal data Ex-U.S. regulatory strategy
Revenue
$3.70M
▲ 61.8% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Confident tone AMT-130 pivotal data and regulatory progress Huntington's disease competitive positioning BLA readiness and manufacturing (PPQ/CMC)
Revenue
$5.26M
▼ 52.7% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
Confident tone AMT-130 Huntington's program and BLA pathway Regulatory designations and FDA interactions Pipeline expansion across other gene therapy programs
Revenue
$1.57M
▼ 81.5% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
uniQure N.V. (QURE) Q2 2022 Earnings Call
Revenue
$497,000
▼ 99.9% YoY
Diluted EPS
$-0.84
▼ 109.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
uniQure N.V. (QURE) Q2 2020 Earnings Call
Revenue
$1.53M
▼ 38% YoY
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 1590560 CUSIP N90064101 13F (30d) 8 filings 8 filers Visit website Investor relations